论文部分内容阅读
文章对新型抗肿瘤药物,表皮生长因子受体(EGFR)酪氨酸激酶抑制剂吉非替尼的合成进展进行了综述,并讨论了各路线优缺点及可行性。
In this paper, the synthesis of gefitinib, a novel antitumor drug and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, was reviewed. The advantages, disadvantages and feasibility of each route were discussed.